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Asthma is characterised by reversible airway 
obstruction, increased bronchial hyper-respon-
siveness (BHR) and chronic inf lammation. 
However, it is recognized that asthma is het-
erogeneous regarding the underlying clinical 
and inflammatory phenotypes present. In the 
UK, 5.4 million people are currently receiving 
treatment for asthma, which represents a major 
burden with respect to mortality, morbidity and 
National Health Service costs – estimated to be 
GB£1 billion per year. Current asthma medica-
tions (FIGURE 1) are effective in most but not all 
patients, with a subgroup of patients (<5%) that 
have limited disease control, persistent symp-
toms and exacerbations despite medication use 
[1]. There is a need for alternative therapies for 
these refractory patients and a need to target 
existing drugs towards those subjects most likely 
to gain clinical benefit.
Asthma is considered a complex genetic disease 
involving the interaction of multiple genes with 
each other (gene–gene interactions) and the 
environment (gene–environment interactions), 
including; infection (viral, bacterial), allergen 
exposure, pollution and smoking [2,3]. There has 
been good progress in recent years in asthma-
susceptibility gene discovery, driven mainly by 
genome-wide association (GWA) approaches 
that investigate up to 1 million single-nucleotide 
polymorphisms (SNPs) in large populations 
composed of thousands of individuals. Asthma 
susceptibility genes identified using this approach 
include IL1RL1, IL18R, TSLP, PDE4D, MHC II, 
DQ, IL-33, LRRC32, SMAD3, ORMDL3, 
GSDMB and IL2RB [4–9].
Pharmacogenetics in asthma
Pharmacogenetics, the investigation of the effect 
of genetic variability on treatment response or 
risk of serious side effects, is the first step in 
developing personalized prescribing. Thus far, 
asthma studies have mainly been limited to 
small numbers of subjects (<100 subjects) and 
restricted to candidate gene/pathway SNPs 
using retrospective analyses. These studies have 
focused on pharmacodynamic aspects – for 
example, changes in forced expiratory volume 
in 1 s (FEV
1
) or symptom scores postmedication 
stratified based on genotype (TABLE 1).
Improving our understanding of asthma 
pharmacogenetics for the selected targeting 
of the right therapy to the right patient aims 
to reduce hospital admissions due to poorly 
controlled asthma as well as reducing asthma 
fatalities. Current asthma medications have few 
apparent severe adverse drug effects; however, 
some detrimental effects have been observed – for 
example arrhythmias with E
2
-adrenergic receptor 
agonists and osteoporosis with steroids. Similarly, 
Churg–Strauss syndrome has been linked to 
leukotriene modifier therapy. Pharmacogenetic 
knowledge, leading to targeted therapy, has 
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the potential to reduce exposure to these effects. Asthma 
pharmacogenetics also has a role to play in the development of 
new therapeutics –  for example improving the accuracy and safety 
of Phase II trials. In the current review we provide:
฀•฀฀A comprehensive update on recent pharmacogenetic 
developments in the major drug classes used to treat asthma 
– that is, E
2
-adrenergic receptor agonists, corticosteroids and 
leukotriene modifiers;
฀•฀฀Preliminary pharmacogenetic data for newer drugs in Phase II 
development;
฀•฀฀Discuss the potential pharmacogenetic considerations for newer 
targets identified in GWA studies in asthma.
Pharmacogenetics of current asthma therapy: 
an update
There are currently three major classes of asthma pharmacotherapy:
฀•฀฀Inhaled E
2
-adrenergic receptor agonists for the relief of airway 
obstruction, which are further divided into short-acting 
E
2
-adrenergic receptor agonists (e.g., salbutamol) that are used 
Table 1. Recently identified pharmacogenetic effects on current asthma therapies.
Gene Key polymorphism Pharmacogenetic effect in asthma
E
2
-adrenergicreceptor agonists (e.g., salbutamol and salmeterol)
ADRB2 Arg16Gly
Gln27Glu
PolyC (3’UTR)
Mixed reports (see text)
Mixed reports (see text)
Counteracts ADRB2 downregulation
ARG I rs2781659 (5’ region) Haplotypes increase ARG1 transcription, leading to improved 
response to E
2
AR agonist
GSNOR rs1154400(5’ region) Differential response to E
2
AR agonist
GSNOR haplotypes determine GSNOR transcription
Leukotriene modifiers (e.g., montelukast, zarfirlukast and zileuton)
ALOX5 rs2115189 (intronic) 
rs4987105 (Thr120Thr)
rs4986832 (5’ region)
Causes a differential response to zileuton and montelukast 
therapy (FEV
1
 change)
Cause differential response to montelukast therapy (FEV
1
 
change)
LTC4S A-444C
rs272431 (intronic)
Associated with LTRA and LTSI response (FEV
1
 change) in some 
but not all studies
Causes a differential response to zileuton therapy (FEV
1
 change) 
CYSLT2 rs91227 (3’ UTR)
rs912278 (3’ UTR)
Associated with morning PEF in subjects taking montelukast
MRP1 rs119774 (intronic) Causes a differential response to zileuton and montelukast 
therapy (FEV
1
 change)
OATP2B1 rs12422149 (Arg312Gln) Reduced morning plasma concentrations of montelukast, 
resulting in lack of clinical benefit
Corticosteroids (e.g., prednisolone and beclomethasone)
CRHR1 rs242941 (intronic) Associated with corticosteroid response (FEV
1
 change) 
TBX21 rs224001 (His33Gln) Improvements in BHR with corticosteroid treatment
NK2R rs7703891 (Gly231Glu) Improved asthma control with corticosteroid treatment
STIP1 rs4980524 (intron 1)
rs6591838 (intron 1)
rs2236647 (intron 5)
Associated with corticosteroid response (FEV
1
 change) 
DUSP1 rs881152 (5’ region) Associated with bronchodilator response and asthma control in 
the presence of corticosteroids
FCER2 rs28364072 (intronic) Associated with asthma exacerbations in the presence of 
corticosteroids
GLCCI rs37972 (5’ region) Associated with corticosteroid response (FEV
1
 change); 
potential transcriptional mechanism
E
2
AR: E
2
-adrenergic receptor; BHR: Bronchial hyper-responsiveness; FEV
1
: Forced expiratory volume in 1 s; LTRA: Leukotriene receptor antagonist; LTSI: Leukotriene 
synthesis inhibitor; PEF: Peak expiratory flow; UTR: Untranslated region.
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for the short-term relief of bronchospasm and long-acting 
E
2
-adrenergic receptor agonists (i.e., salmeterol) that are used 
for the long-term treatment of bronchospasm;
฀•฀฀Inhaled and systemic corticosteroids (e.g., beclomethasone and 
prednisolone);
Figure 1. Targets of current asthma medication. Corticosteroids cross the cell membrane and bind to receptors that are stabilized by 
regulatory proteins. The glucocorticoid receptor (GR) then crosses the nuclear membrane, binds to a response element and modulates 
transcription. E
2
-adrenergic receptor agonists bind to the E
2
-adrenergic receptor and mediate smooth muscle relaxation via PKA and 
regulate various genes via the transcription factor CREB. The cysteinyl leukotrienes in FIGURE 1 LTC
4
, LTD
4
 and LTE
4
,and dihydroxy 
leukotriene LTB
4
 are synthesized from arachidonic acid in a series of steps via an enzymatic cascade as depicted. Following translocation 
into the extracellular space, cysteinyl leukotrienes activate their cognate GPCRs (including CYSLTR1) and mediate a variety of effects such 
as smooth muscle contraction.  
AC: Adenylcyclase; ALOX5: Arachidonate 5-lipoxygenase; E
2
AR: E
2
-adrenergic receptor; cAMP: Cyclic adenosine monophosphate; 
cysLTR: Cysteinyl Leukotriene receptor; CREB: Cyclic AMP response element-binding; DAG: Diacyl glycerol; GC: Glucocorticoid; 
GPCR: G-protein-coupled receptor; GR: Glucocorticoid receptor; IP3: Inositol-triphosphate; LTA
4
: Leukotriene A
4
; LTB
4
: Leukotriene B
4
; 
LTC
4
: Leukotriene C
4
; LTD
4
: Leukotriene D
4
; LTE
4
: Leukotriene E
4
; LTC4S: Leukotriene C4 synthase; LTA4H: Leukotriene A4 hydrolase; 
LTSI: Leukotriene synthesis inhibitor; LTRA: Leukotriene receptor antagonist; PKA: Cyclic-AMP dependent protein kinase; PKC: Protein 
kinase C; PLC: Phospholipase C.
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฀•฀฀Leukotriene receptor antagonists (LTRAs) (e.g., montelukast 
and zafirlukast), and leukotriene synthesis inhibitors (LTSIs; 
e.g., zileuton, although LTSIs have not been licensed for use in 
the UK.
These medications are used in a stepwise approach (British 
Thoracic Society guidelines [10]), changing as the patient’s outlook 
improves or worsens. The fact that patient response to medication 
is highly heterogeneous warrants approaches to develop a more 
personalized approach to asthma treatment. In the next sections 
we provide an update on the pharmacogenetic aspects of cur-
rent asthma medication and focus on more recent findings. For a 
comprehensive review of earlier studies of the pharmacogenetics 
of these drug classes see reviews [11–15].
E
2
-adrenergic  receptor agonists 
E
2
-adrenergic receptor agonists act by binding to the E
2
-adrenergic 
receptor, a 413-amino-acid G-protein-coupled receptor encoded 
by an intronless gene (ADRB2) located on chromosome 5q31.32. 
Receptor binding results in the activation of adenylcyclase 
through stimulatory GDs proteins that activate protein kinase A. 
The latter phosphorylates several target proteins, resulting in a 
decrease in intracellular calcium, importantly causing smooth 
muscle relaxation in the airways.
ADRB2 is highly polymorphic with 49 SNPs and two insertion/
deletion variants validated to date [16]. ADRB2 has been extensively 
studied for its pharmacogenetic effects on E
2
-adrenergic receptor 
agonist responses. Most studies have focused on the role of 
nonsynonymous coding-region polymorphisms Arg16Gly, 
Gln27Glu, Val34Met and Thr164Ile [17]. The frequency of the 
position 16 and 27 polymorphisms were found to be 59% at 
Arg16Glu and29% at Gln27Glu in the Caucasian population 
[17]. The Val34Met and Thr164Ile polymorphisms are rare, with 
approximate frequencies of <0.001 and 0.05%, respectively. 
Although the Arg16 variant has been associated with an enhanced 
acute response to E
2
-adrenergic receptor agonist a decline of 
asthma control following prolonged use and a subsensitivity of 
response for bronchoprotection. Several studies have failed to 
reproduce these effects. Therefore, a common consensus on the 
contribution of Arg16 has yet to be reached. At least 12 different 
haplotypes (a specific combination of SNPs across the gene) 
have been described in the ADRB2 gene [18], which may explain 
the lack of consensus examining genotype effects in isolation 
[11]. Interestingly, recent GWA studies have failed to identify 
a signal to ADRB2 suggesting this gene is not a major asthma 
susceptibility gene [4–9].
In vitro work using cell lines has identified functional effects 
of these E
2
-adrenergic receptor coding region polymorphisms, 
including the Thr164Ile variant receptor that caused impairment 
in agonist binding and reduced adenylcyclase activity. Enhanced 
agonist-mediated receptor downregulation of the Gly16 variant and 
resistance to downregulation of the Glu27 variant were also observed 
(reviewed in [11,12,14,15]). A recent study did not identify a significant 
effect of the common ADRB2 coding region polymorphisms on 
responses to a range of E
2
-adrenergic receptor agonists, including 
indacaterol in vitro [19]. However, this study did confirm that the 
Thr164Ile variant receptor produced impairment agonist-mediated 
cAMP production in these recombinant cell lines [19].
More recent clinical studies have again been hindered by 
small sample sizes and conflicting results; for example, Lee 
and colleagues identified an association between the Gln27Glu 
and terbutaline nebulizer response (percentage change in peak 
expiratory flow rate ['PEFR (%)]) Gln/Gln = 8.2 ± 9.4%, Glu/
Glu = 23.4 ± 14.4; p < 0.05) and an absence of effect for the 
Arg16Gly polymorphism in children. However, it should be noted 
that these outcomes were only based on 27 patients [20]. In one of 
the largest studies to date, Basu and colleagues recently identified 
an increased risk of exacerbations per copy of Arg16 in 1182 young 
(3–22 years) asthmatic patients (odds ratio [OR]: 1.30; 95% CI: 
1.09–1.55; p = 0.003) on daily exposure to E
2
-adrenergic recep-
tor agonists (regular inhaled corticosteroids plus salbutamol on 
demand and regular inhaled corticosteroids plus salmeterol and 
salbutamol on demand groups) [21]. Importantly, this effect was 
driven by asthma patients that used salbutamol and/or salmeterol 
daily [21]. While an interesting finding, the authors highlight the 
limitations of the study, namely that all participants were using 
E
2
-adrenergic receptor agonists as relievers and a study arm of non-
E
2
-adrenergic receptor agonist reliever use would have provided 
clearer interpretation for the detrimental effects of salbutamol/
salmeterol in the Arg16 subjects. While this large study suggested 
a pharmacogenetic effect of the Arg16 variant on adverse effects 
of E
2
-adrenergic receptor agonists, it is important to note that 
previous large studies have failed to observe a clinically relevant 
effect of these polymorphisms. In a study of 2250 asthma patients 
randomly assigned to budesonide plus formoterol maintenance 
and reliever therapy; fixed dose budesonide plus formoterol; or 
fixed dose fluticasone plus salmeterol for 6 months, no overall 
effect of the Gly16Arg genotype was found on clinical outcomes 
including; exacerbations and secondary end point FEV
1 
[22]. 
The different study designs may underlie these differential 
outcomes, for example, in a study of 2250 subjects, patients were 
not stratified based on as-needed reliever use (increase or decrease 
daily). Interestingly, salmeterol has been further investigated 
in a prospective study exploring the potential pharmacogenetic 
effects of 11 ADRB2 SNPs in patients taking fluicasone/salmeterol 
(n = 268) or salmeterol alone (n = 266) [23]. The main conclusion 
from this study was that there was a lack of pharmacogenetic effect 
for Arg16Gly on key outcomes, including morning peak flow and 
symptom-free days; however, modest associations were observed for 
other SNPs in ADRB2 regulatory regions, although it is unlikely 
these would survive correction for multiple testing [23]. Another key 
observation from this study was the lack of any significant adverse 
effects following active treatment withdrawal that have previously 
been described post E
2
-adrenergic receptor agonist (salbutamol) 
withdrawal [24]. An absence of effect of the Arg16 genotype on 
fluicasone/salmeterol clinical outcomes, including lung function 
and symptoms, was also observed in a smaller, multicenter, 
randomized, double-blind, placebo-controlled trial in adult asthma 
subjects over a 18-week period [25]. Importantly, in this prospective 
study the Arg/Arg and Gly/Gly subjects were matched (morning 
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peak expiratory flow, FEV
1
, symptom scores) prior to the trial to 
maximize genotype-specific effects [25].
While the majority of studies have focused on Arg16Gly as 
outlined above, ADRB2 is highly polymorphic, with potential 
polymorphisms in the regulatory regions. Recent in vitro 
approaches using ‘whole-gene’ transfection have identified 
differential effects on receptor expression and downregulation 
that are haplotype driven, by studying eight common haplotypes 
based on 26 SNPs [26]. Interestingly this study identified four 
common haplotypes with elevated receptor expression and two 
haplotypes with enhanced receptor downregulation. The clinical 
significance of these findings remains to be resolved; however, 
previous haplotype-based data have identified significant clinical 
effects, suggesting that multiple polymorphisms may be clinically 
relevant [11]. Recent interest has focused on 3´UTR investigations 
that have identified a variable-length poly-C tract polymorphism 
that altered ADRB2 expression and receptor downregulation 
in vitro [27], but was not found to associate with clinical responses 
to salmeterol when investigated in an asthma population [28].
Overall, recent larger prospective studies have failed to identify 
a pharmacogenetic effect of the common ADRB2 Arg16Gly and 
Gln27Glu polymorphisms, questioning the initial findings from 
smaller studies but also the translation of in vitro functional work 
to a clinical setting where single SNPs are anticipated to have 
modest effect size on clinical outcome measures. However, there 
still remains evidence of clinically relevant effects – that is, in 
carefully selected individuals that are using daily E
2
-adrenergic 
receptor agonist relievers, as outlined by Basu and colleagues [21].
Novel regulators of E
2
-adrenergic receptor agonist 
responses
The mechanism of action of E
2
-adrenergic receptor agonists 
is complex and multifactorial, and a large number of gene 
polymorphisms may be expected to influence the efficacy of the 
drug. While cAMP is considered a major second messenger in 
the beneficial effects of this drug class – that is, smooth-muscle 
relaxation, several other mechanisms may be of relevance. Using 
a novel algorithm implemented in a family-based association test, 
Litonjua et al. screened the association of 844 genotyped SNPs 
in 111 candidate genes (42 involved in E
2
-adrenergic receptor 
signalling/regulation, 28 genes involved in glucocorticoid 
regulation, 41 genes from prior asthma association studies) in 209 
children and their parents participating in the Childhood Asthma 
Management Program for their association with acute response to 
inhaled E
2
-adrenergic receptor agonists. This study identified the 
Arginase 1 (ARG1) SNP rs2781659 as being significantly associated 
with bronchodilator response (p = 0.047) [29]. In agreement, 
polymorphisms spanning ARG1 have been identified that influence 
patient response to salbutamol in a recent candidate gene study 
involving 221 asthma subjects [30]. The ARG1 polymorphisms 
identified in both studies were in linkage disequilibrium (inherited 
together), suggesting a common causative mechanism involving 
potential transcriptional regulation as these polymorphisms were 
predominantly 5´  to the gene. This alteration in transcription 
has now been confirmed in promoter-reporter studies, with the 
key ARG haplotype associated with improved bronchodilator 
response driving the highest level of ARG1 promoter activity [31]. 
Interestingly, in the study by Vonk and colleagues, ARG2 SNPs 
were also associated with patient responses to salbutamol [30]. 
Data from guinea pig models of allergic airway disease suggest 
that arginase enzymes deplete stores of L-arginine, a nitric oxide 
synthase substrate, in the airways leading to decreased nitric oxide 
levels, which normally acts to relax smooth muscle, resulting in 
airway hyper-responsiveness [32,33].
Recently, GSNOR SNP (rs1154400, promoter region) 
was associated with a decreased response to salbutamol in 
107 African–American children [34]. Within the same study, 
a post-hoc multilocus analysis identified that a combination of 
rs1154400 with ADRB2 Arg16Gly, Gly27Glu and the carbamoyl 
phosphate synthetase-1 (CPS1) SNP rs2230739 gave a 70% 
predictive value for lack of response to therapy [34]. This implies 
that pharmacogenetic regulation of E
2
-adrenergic receptor agonist 
therapy may depend on several loci acting together via gene–
gene interactions. In confirmation, four out of five SNPs tested 
within GSNOR were associated with asthma patient responses 
to salbutamol in 168 Puerto Rican asthma patients [35]. These 
SNPs were also associated with asthma susceptibility and the 
key risk haplotype was associated with increased transcriptional 
activity based on promoter-reporter studies [35]. GSNOR is an 
alcohol dehydrogenase that breaks down S-nitrosoglutathione, an 
endogenous bronchodilator [36]. In addition, S-nitrosoglutathione 
regulates nitrosylation of proteins leading to alterations in 
function, including G protein-coupled receptor kinase 2, which 
phosphorylates and desensitises the E
2
-adrenergic receptor [37].
The identification of those patients at risk from potential adverse 
effects of E
2
-adrenergic receptor agonists remains a critical clinical 
question, as does the targeting of this class of drug to those patients 
most likely to gain benefit. While there has been clear progress 
with respect to study design for example, examining haplotypes 
instead of genotypes in isolation and adequately powered studies 
using thousands of individuals – there is still a need for large 
prospective studies of asthma patients with matched phenotypes 
and carefully controlled covariates including environmental 
influences. Similarly, these studies would benefit from GWA 
approaches and the identification of gene–gene interactions.
Leukotriene modifiers
Cysteinyl leukotrienes contribute to the inflammatory process 
in asthma and are synthesized from arachidonic acid via the 
5-lipoxygenase pathway (FIGURE 1). In the synthesis reaction, 
arachidonic acid is converted to 5-hydroperoxyeicosatetraenoic acid 
and leukotriene A
4
 (LTA
4
) by membrane-bound 5-lipoxygenase 
(5LO/ALOX5) and 5-lipoxygenase activating protein (FLAP/
ALOX5AP). LTA
4
 is then converted to leukotriene B
4
 (LTB
4
) by 
LTA
4 
hydrolase (LTA4H) or is conjugated with reduced glutathione 
by leukotriene C
4
 (LTC
4
) synthase to form LTC
4
. LTC
4
 is then 
transported to the extracellular space via the multidrug resistance 
protein 1 (MRP1) (FIGURE 1). Leukotriene modifiers include LTSIs, 
which act by targeting the leukotriene pathway, blocking cysteinyl 
leukotriene production from arachidonic acid, while LTRAs block 
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cysteinyl leukotrienes from binding to their primary receptor, 
CYSLTR1.
There are excellent data demonstrating heterogeneity in patient 
responses to LTRAs – that is, a key study by Malmstrom and 
colleagues investigating the efficacy of montelukast (10 mg 
once daily) in chronic asthma (12 weeks; n = 895) potentially 
suggesting genetics may influence response [38]. Similarly, there 
have been extensive candidate gene studies investigating the effect 
of SNPs on LTSI and LTRA responses, with pharmacogenetic 
associations observed for polymorphisms within ALOX5, 
ALOX5AP, LTC4S, CYSLTR1, CYSLTR2 and MRP1. However, 
few of these associations have been replicated [11–13]. More recent 
studies have again focused on enzyme/receptor genes of the 
leukotriene pathway; however, novel pharmacogenetic effects 
have also been found – that is, OATP2B1 and montelukast 
absorption [39].
5-lipoxygenase (ALOX5)
5-lipoxygenase catalyzes the conversion of arachidonic acid 
to LTA
4
. The ALOX5 gene has been mapped to chromosome 
10q11.2, which spans approximately 82 kb and is composed 
of 14 exons and 13 introns. Extensive evidence suggests that 
polymorphisms spanning the ALOX5 gene influence clinical 
responses to LTRAs and LTSIs; most notably, a functional 
Sp1 repeat polymorphism in the promoter region of the gene 
associated with altered gene transcription was associated with 
response to the LTSI, ABT-761 [13,40]. More recently, studies 
have included multiple polymorphisms and larger cohorts 
looking at both LTRA and LTSI responses. Tantisira and 
colleagues identified an association between ALOX5 intronic 
SNPs; rs892690, rs2029253 and rs2115819, and change in 
FEV
1
 postzileuton treatment, in a cohort of 577 asthma patients 
[41]. Importantly, the rs2115819 SNP was also a predictor of 
response to montelukast in a previous study of 252 asthma 
subjects using percentage change in FEV
1
 as the primary 
outcome [42]. In both cases the GG versus GA or AA had the 
greatest improvement in FEV
1
 – for example, change in FEV
1
 
% predicted postmontelukast GG = 30%, GA = 4.4% and 
AA = 2.0% (p = 0.017) [42]. The potential lack of signal for 
the rs892690 and rs2029253 SNPs in the montelukast study 
may be due to the reduced power of this study compared with 
the zileuton study. The functional significance of these intronic 
SNPs remains to be resolved. Klotsman and colleagues identified 
two ALOX5 SNPs (rs4987105 [synonymous Thr120Thr] and 
rs4986832 (5 -´region)) that were associated with improvements 
in peak expiratory flow on treatment with montelukast in a 
12 week study in 174 asthma patients – for example, rs4987105: 
CC = 33.7 (n = 110), CT = 55.3 (n = 42) and TT = 94.8 
(n = 10) [43].
Leukotriene C
4
 synthase (LTC4S)
Leukotriene C
4
 synthase conjugates glutathione with LTA
4
 to 
form LTC
4
, the first cysteinyl leukotriene in the 5-lipoxygenase 
pathway. The human LTC
4
 synthase gene (LTC4S) consists 
of five exons, ranging between 71 and 257 bp, spans 2.51 kb, 
and has been mapped to chromosome 5q35. A gene promoter 
polymorphism (A-444C, rs730012) has been previously 
associated with increased production and expression of 
LTC
4
 by blood eosinophils (C allele) [44]. Five of the ten 
published pharmacogenetic studies on the LTC4S -444 A>C 
polymorphism showed an improved response to LTRAs (FEV
1
) 
from patients carrying the C allele [42,44–47], although results 
were not always statistically significant [44,46,47]. The other 
f ive published studies could not reproduce these f indings 
[43,48–51]. More recently, a study of zileuton responses (FEV
1
 
change over time) in 577 asthma subjects failed to identify 
a pharmacogenetic effect of the LTC4S-444 polymorphism. 
However, an alternative LTC4S polymorphism (rs272431, 
intron 1) was associated with improved responses (mean FEV
1
 
AA = 2.30 l; AC = 3.11 l; p = 0.006) [41]. As these results were 
obtained in different populations and using different end points, 
the relative contribution of LTC4S polymorphism to LTRA 
or LTSI therapeutic responses in asthma are still unclear. We 
therefore suggest that further studies are required in multiple 
ethnic background populations in order to evaluate these 
multiple polymorphisms spanning the LTC4S gene.
CYSLTR1 & CYSLTR2
The target of LTRAs such as montelukast, pranlukast and 
zafirlukast, is the CYSLTR1 receptor. CYSLTR1 is 337 amino 
acids long, 38.5 kDa and encoded by an intronless gene on 
Xq13-21. CYSLTR2 resides on chromosome 13q14. The gene 
is 2548 bp long, encoding 346 amino acids. Recently, York and 
colleagues identified that polymorphisms within CYSLTR1 (in 
combination with ALOX5 SNPs) are associated with responses 
to montelukast [52]. However, in isolation CYSLTR1 SNPs tested 
to date do not influence responses to montelukast [42] or zileuton 
[40]. Interestingly, an association between CYSLTR2 (rs91227 and 
rs912278 [3 -´UTR]) and morning PEF (e.g., rs91227 TT = 29.1 
[n = 60]; TC = 41.3 [n = 75]; CC = 71.6 [n = 28; p = 0.008]) 
was identified in a recent study of 174 asthma subjects taking 
montelukast for 12 weeks [43].
Novel regulators of leukotriene modifier drugs
Mougey and colleagues recently identified that solute carrier 
organic anion transporter family member 2B1 (SLCO2B1, 
alternative name; organic anion transported SB1; OATP2B1) 
mediates montelukast permeability using a Madin–Darby 
canine kidney II cell line overexpressing recombinant 
OATP2B1 [39]. The authors went on to identify that a key 
nonsynonymous SNP in OATP2B1, rs12422149, Arg312Gln 
was associated with reduced morning plasma concentrations of 
montelukast following an evening dose during 1- or 6-month 
treatment in 80 asthma subjects of mixed ethnic background. 
The GA (Arg/Gln) genotype hadapproximately20% lower 
montelukast concentration than the GG (Arg) group at 1 month 
and an approximate 30% lower concentration at 6 months [39]. 
Importantly, carriers of the variant A allele did not benefit 
from montelukast administration, as determined by a symptom 
utility score [39]. These authors went on to replicate the effect 
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of OATP2B1, rs12422149 and Arg312Gln on montelukast 
absorption in a further study [53]. This study highlights the 
importance of genetic variation on both pharmacokinetics and 
the pharmacodynamics in asthma medication. Similarly, SNPs 
within another transporter protein, MRP1 (alternative name 
ABCC1), that is, rs119774 have been associated with montelukast 
response (change in FEV
1
 % predicted; CC = 2.2%; CT = 24%; 
p = 0.004) [54]. More recently, multiple MRP1 SNPs have been 
associated with responses to zileuton, including the rs119774 
SNP, confirming the potential pharmacogenetic significance 
of this MRP1 SNP marker [41]. This SNP is intronic and the 
underlying mechanism explaining these pharmacogenetic effects 
remains to be resolved.
Overall, there has been good progress in the pharmacogenetics 
of leukotriene modifier therapy in asthma, with SNPs in key 
leukotriene synthesizing enzymes (e.g., ALOX5) showing 
association with both LTRA and LTSI responses. The 
molecular mechanisms underlying these effects require 
further study. Importantly, studies have begun to identify the 
importance of genetic variation on both pharmacokinetics 
and pharmacodynamics, including the role of polymorphisms 
spanning multiple transporter proteins. However, these studies 
require replication in larger cohorts to adequately determine the 
clinical implications of these findings.
Corticosteroids
Corticosteroids are the most effective and commonly (inhaled 
dosage form) used drugs for the treatment of chronic asthma, 
but may result in serious adverse effects such as osteoporosis and 
adrenal suppression. Inhaled, oral and intravenous corticosteroids 
– for example, prednisolone and beclomethasone – have been 
central in the management of asthma for the last 30 years. 
There is substantial interindividual variability in the response 
to corticosteroids [38], which is highly reproducible, properties 
that support a genetic basis for the response to corticosteroids 
in asthma.
Initial pharmacogenetic investigations studied the glucocorticoid 
receptor gene (GR; NR3C1), which maps to chromosomal region 
5q31, a region associated with multiple asthma phenotypes. 
Several polymorphisms have been described in the GR gene with 
functional consequences, that is, a Val641Asp polymorphism 
influences the binding affinity for dexamethasone; however, 
several of the polymorphisms are rare and their functional 
significance questionable [11]. Haplotype analyses identified an 
association with a lower response to dexamethasone using a 
suppression test in 216 UK Caucasians [55].
SNPs in the corticotrophin-releasing hormone receptor 1 
(CRHR1) have been found to be associated with response to 
inhaled corticosteroid treatment in three asthmatic cohorts 
using a candidate gene approach (131 SNPs in 14 genes; n = 1117 
asthma subjects in total; end point % change in FEV
1
 following 
8 weeks treatment) [56]. For example CRHR1 SNP rs242941 
(intronic) showed genotype-specific responses; FEV
1 
% predicted 
change; AA = 13.28 ± 3.11%, GG = 5.49 ± 1.40; p = 0.025 
(n = 470 adult asthma subjects). CRHR1 is thought to be involved 
in the regulation of endogenous levels of corticosteroid and 
therefore may be predicted to influence responses to exogenously 
administered corticosteroid. This study was the first study to 
show a pharmacogenetic effect for steroid efficacy in an asthmatic 
cohort.
Using BHR (4-year change) as an outcome in asthma subjects, 
TBX21 nonsynonymous SNP (rs2240017C/G, His33Gln) 
was shown to be a predictor of improvements in BHR post-
corticosteroid treatment in children (G allele gave greatest 
improvements), although the allele frequency of this SNP is 
low in Caucasians (MAF a0.04) and thus few subjects (n = 5) 
contributed to this observation [56]. TBX21 is a transcription 
factor involved in T-cell differentiation, particularly Th1/Th2, 
lineages and the authors demonstrated that dexamethasone 
can suppress TBX21 levels in human T cells [56]. Previous data 
have suggested that TBX21 is involved in the development of 
BHR, with TBX21- /- mice spontaneously developing BHR [57]. 
Subsequently, Ye and colleagues demonstrated that the TBX21 
(His33Gln) polymorphism was significantly associated with 
improved asthma control in the presence of corticosteroids, 
although the alternative allele to that described previously was 
associated with greater control in 53 Korean asthma patients 
during 5–12 weeks treatment [58]. In the same study, Ye and 
colleagues identified that Neurokinin 2 receptor (NK2R) SNP 
(rs77038916G/A, Gly231Glu) was associated with improved 
asthma control in the presence of corticosteroid, with the 
G allele (Gly) associated with greatest improvement [58]. 
Neurokinin A induces bronchoconstriction and inflammation, 
therefore modulation of the neurokinin receptor may influence 
the magnitude of these responses. Amino acid 231 is in the 
third intracellular loop of the receptor, which is involved in 
agonist-mediated signaling, providing a putative mechanism.
Hawkins and colleagues have recently reported that 
multiple SNPs in stress-induced phosphoprotein 1 (STIP1) 
were associated with variable FEV
1
 responses to treatment 
with inhaled flunisolide in 382 asthma subjects [59]. This 
study interrogated SNPs spanning eight candidate genes 
and identified STIP1 SNPs rs4980524 (intron 1), rs6591838 
(intron 1) and rs2236647 (intron 5) affecting percent change 
in FEV
1 
in response to flunisolide at 4 and 8 weeks. For 
example, rs4980524; AA = 5.10 ± 17.16, AC = 5.40 ± 19.00, 
CC = 11.03 ± 24.03; p = 0.044 at 4 weeks [59]. STIP1 is an 
adaptor protein that coordinates functions with HSP70 and 
may be involved in formation of the glucocorticosteroid 
receptor heterocomplex.
Dual-specificity phosphatase 1 (DUSP1) has dual specificity 
for tyrosine and threonine and inactivates p38 MAPK. Recently, 
several SNPs, including a 5´ -region SNP rs881152, were associated 
with bronchodilator response and asthma control in the presence 
of corticosteroid using a cohort of asthma patients (n = 430) [60].
The mechanism underlying these effects is unclear; however, 
it was suggested that corticosteroids induce DUSP1 expression 
(which may be altered in carriers of the rs881152 5´ -region SNP), 
which influences the ability of DUSP1 to target the p38 MAPK 
signaling pathway.
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A SNP within FCER2 (the low-affinity IgE receptor) has 
been shown to be associated with asthma exacerbations during 
budesonide therapy in 311 asthmatic children [61]. In particular, 
SNP T2206C (rs28364072, intronic) was identified (relative risk of 
severe exacerbations while taking budesonide: 3.62; 95% CI: 2.02–
6.49 for homozygous [CC] versus all other genotype groups) [61]. 
Importantly, FcHRII expression on lymphoblastoid cells was shown 
to be dependent on T2206C genotype, with the C allele conferring 
lower expression. The C allele was associated with elevated IgE levels 
in the 311 asthma patients [61]. This pharmacogenetic association 
has now been replicated in two further asthma cohorts (n = 386 
and 939, respectively), with the 2206C allele being associated 
with increased hospital visits (OR: 1.91; 95% CI: 1.08–3.40) and 
uncontrolled asthma (OR: 2.64; 95% CI: 1.00–6.98) in patients 
receiving corticosteroid [62]. It is potentially not surprising that 
this polymorphic variation in an IgE receptor influences receptor 
expression, which alters IgE levels and is associated with more severe 
forms of asthma and, in turn these subjects cannot be adequately 
controlled by corticosteroid treatment.
During the writing of this review, the first GWA study in 
asthma pharmacogenetics was published identifying GLCC1 
SNPs as determinants of glucocorticoid responses in 935 asthma 
subjects [63]. This study examined 534,290 SNPs using the 
HumanHap 550v3 BeadChip in an initial cohort of 403 parent 
and child trios, with the primary outcome being change in FEV
1 
and identified 100 SNPs of highest power for follow on. One 
SNP, GLCC1 rs37972C/T, was associated with change in FEV
1
 
post-corticosteroid in three out of four cohorts tested; change 
in FEV
1
 4 weeks post-treatment; cohort 1: CC = 11.7 ± 2.6, 
TT = 2.7 ± 3.8; cohort 2: CC = 29.5 ± 1.7, TT = 3.1 ± 1.7; cohort 
3: CC = 11.8 ± 1.8, TT = 3.1 ± 2.7; and cohort 4: CC = 9.8 ± 1.6, 
TT = 4.5 ± 2.8 [63]. rs37972 is located in the promoter region 
of GLCC1 and is in linkage disequilibrium with another SNP, 
rs37973, which together were shown to lead to allele-specific 
transcription using reporter-based approaches in several cell 
lines; the rs37972C gave lower activity [63]. The mechanism 
underlying this novel finding and clinical significance requires 
further clarification.
Pharmacogenetics of asthma drugs in Phase II 
development
Progress in asthma therapy has mainly been through new 
compounds/indications within existing drug classes – for example, 
improved duration of action of long-acting E
2
-adrenergic receptor 
agonists. Drug development has also focused on areas including: 
฀•฀฀Cytokine inhibition; for example, anti-IL-5 (mepolizumab), anti-
TNFD (etanercept, soluble TNFR), anti-IL-13 (lebrikizumab);
฀•฀฀Chemokine receptor antagonists; for example, chemokine 
(C-X-C motif) receptor 2 (CXCR2; SCH527123);
฀•฀฀Signalling pathway inhibitors with anti-inflammatory effects; 
for example, targeting p38 MAPK (SD-282), PDE4 
(roflumilast) [64].
The targeting of specific mediators is unlikely to provide a thera-
peutic option for asthma in a broad sense; however, targeting 
subpopulations has demonstrated clinical efficacy. In a recent 
clinical trial of anti-IL-5 (mepolizumab), careful selection of 
patients based on refractory asthma and sputum eosinophilia 
(>3%) counts demonstrated a robust clinical benefit; for exam-
ple, reduced exacerbation rates, 2.0 versus 3.4 mean exacerba-
tions per subject following 50 weeks treatment with mepolizumab 
or placebo respectively [65]. Similarly, a recent study examining 
anti-IL-13 antibody therapy (lebrikizumab) efficacy in asthma 
used preselected individuals with IL-13/Th2-dominated asthma 
(as defined by total IgE, blood eosinophilia and serum periostin 
levels) [66]. The asthma patients with a preselected IL-13/Th2 
phenotype showed greatest improvements, including an increase 
in mean baseline FEV
1
 (% predicted) of 8.2% compared with 
the low periostin group – 1.6% following 12 weeks treatment 
[66]. Both of these studies demonstrate that careful selection of 
asthma subjects, in these examples based on phenotype, is critical 
in asthma drug development. It is important to note that serum 
eosinophilia has a clear genetic contribution involving polymor-
phism within IL-5, IL-33, lL1RL1, WDR36 and MYB genes [7] and 
that polymorphisms spanning the IL-13 locus show some of the 
most robust asthma associations to date including in recent GWA 
study [5]. Therefore, it is highly likely that these drug-responsive 
subphenotypes have a pharmacogenetic basis.
Preliminary data supports genetic targeting in Phase II trials of 
newer compounds, as shown in a recent report of a IL-4/IL-13 
dual antagonist (pitrakinra). Polymorphic variation in the target 
receptor for this antagonist, that is, IL4RD significantly influenced 
outcomes in allergic asthma subjects [67]. This antagonist is a 
recombinant form of IL-4 with two amino acid residue changes 
(i.e., a mutein, R121D/Y124D) and was shown to reduce late-phase 
antigen responses (LAR) to inhaled antigen [68]. The LAR was 
defined by changes in FEV
1 
over 4–10 h postantigen following a 
4-week period of active treatment (twice daily, nebulized pitrakinra 
or placebo), with an increased LAR ratio correlating with a reduced 
FEV
1
. Stratification of subjects (pitrakinra n = 15; placebo n = 14) 
into genotype groups for nonsynonymous IL4RA SNP rs1801275 
(Gln576Arg) identified that Arg/Arg carriers had an attenuated 
LAR (p < 0.0001) following pitrakinra treatment compared with 
Gln/Gln or Gln/Arg genotypes. Similarly, stratification based on 
rs1805011 (Glu400Ala) showed an attenuated LAR in the Glu/
Ala group, not the Glu/Glu group [67]. Interestingly, the Arg576 
variant (when in combination with Val75) has been shown to be 
a risk factor for allergic asthma, and can lead to enhanced IL4RD 
signalling post IL-4 stimulation [69]. While preliminary, these 
data suggest that selecting a subgroup of patients with a particular 
genotype where it is anticipated the receptor/pathway may have 
a more dominant role in that individual’s asthma is critical to 
interpreting Phase II clinical trials.
Pharmacogenetic considerations for genes identified in 
recent asthma GWA studies
As our understanding of the genetic basis of asthma increases, 
new drug targets are becoming apparent. Recent GWA studies 
have identified a large number of genes that contribute to the 
susceptibility to develop asthma, including chromosome 17q21 
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(ORMDL3/GSDMB), IL33, IL1RL1/IL18R1, HLA-DQ, IL2RB, 
SMAD3, PDE4D, TSLP and DENND1B, LRRC32 and IL6R 
(TABLE 2). Similarly, multiple genes have been identified using 
positional cloning, such as ADAM33, NPSR1, HLA-G, PCDH1 
and PLAUR [2,3]. It remains largely unknown how these genes 
predispose individuals to specific clinical phenotypes that 
contribute to asthma. However, it is anticipated that polymorphic 
variation within these genes and/or relevant pathways will define 
subgroups and have pharmacogenetic effects on drugs designed 
to target these pathways. To illustrate these concepts, we will 
focus on IL33 and IL1RL1, two genes that show replicated 
association with asthma susceptibility and provide a therapeutic 
opportunity in asthma, and PDE4D a target of asthma drugs 
already in Phase II/III development.
IL-33 receptor antagonists 
IL-33 belongs to the IL-1 cytokine family, which includes IL-1 
and IL-18, and signals via its cognate receptor, ST2 (IL1RL1). 
ST2 is part of the IL-1 receptor/Toll-like receptor (TLR) family 
and is characterized by containing a TLR/IL1R (TIR) signaling 
domain. IL-33/ST2 ligation activates NF-NB and MAPK; 
p38, extracellular receptor kinase1/2 and JNK 1/2 pathways in 
immune cells. A soluble form of ST2, also exists which attenuates 
IL-33 function with respect to inflammatory cell recruitment [70].
As proof-of-principle, treatment with anti-IL-33 significantly 
reduced induction of allergic airway disease in mice, as determined 
by reduced serum IgE and airway eosinophil and lymphocyte 
counts [71]. Importantly, not only induction but also resolution of 
an ongoing allergic airway response was influenced by targeting 
this ligand–receptor interaction [72].
The role of IL-33/ST2 in human asthma remains to be resolved; 
however, IL-33 has been shown to be elevated in airway structural 
cells, including bronchial epithelial cells and airway smooth 
muscle cells in asthma patients [73]. Recent findings suggest that 
IL-33 is one of the earliest cytokines released by airway epithelial 
cells after contact with house dust-mite allergen or the bacterial 
product LPS via TLR4 [74]. Similarly, levels of soluble ST2 in 
serum (the potential decoy receptor) are elevated during asthma 
exacerbation [75]. These data strongly suggest that the IL-33/ST2 
axis are dysregulated in asthma. The IL-33/ST2 axis is the focus 
of intense interest in inflammatory disease, with patents filed by 
Schering Corporation, Millennium Pharmaceuticals and Roche 
Diagnostics.
SNPs spanning IL33 and IL1RL1 have reproducibly been 
associated with asthma susceptibility in the main GWA studies to 
date [5,7,76]. The key IL33 SNPs span approximately90 kb and are 
located in the distal 5´ region (key SNP rs340908; 86.9 kb from 
transcription start site [TSS]), proximal promoter (rs3939286; 
5.7 kb from TSS) or in the first intron (rs2066362) of IL33. It 
is possible that these risk alleles could alter IL-33 expression. 
The IL1RL1 SNPs associated with asthma are more variable 
between studies and map to the IL1RL1 5´ region, for example, 
rs11685480, which has been shown to influence expression levels 
of soluble form of ST2 in serum [77]. In addition, coding region 
variation in the TIR domain, that is, rs10204137 (Glu501Arg), 
rs10192157 (Thr549Ile) and rs10206753 (Leu551Ser), have 
shown associations with asthma [5], suggesting that protein 
structure/receptor signalling may be altered in carriers of these 
asthma risk genotypes.
Taken together, these data strongly suggest that any approach 
to target IL-33 induction and expression; and inhibit IL-33-ST2 
interactions needs to take into account these potentially 
functionally relevant SNPs.
Phosphodiesterase inhibitors
There has been intense interest in PDE4 inhibition as an asthma 
and COPD treatment [78]. Phosphodiesterase enzymes catalyze 
the breakdown of cAMP and cGMP to 5´  monophosphates. PDE4 
inhibition is thought to lead to elevated levels of intracellular 
cAMP, which has many physiological implications; for example, 
Table 2. Asthma susceptibility genes recently identified by genome-wide association studies.
Gene/region Chromosome Function Ref.
IL6R 1q21 Regulatory T-cell function, T-cell differentiation [9]
DENND1B 1q31 Memory T cell functions [8]
IL1RL1 2q11 IL-33 receptor, recruitment/activation of inflammatory cells [5,7]
PDE4D 5q12 Modulates cAMP, role in cell signaling, inflammation and airway smooth muscle 
function
[6]
TSLP 5q22 Activates dendritic cells, role in Th2 immune responses [5]
HLA-DQ 6p21 Cell membrane alloantigens, T-cell responses [5]
IL-33 9p24 Produced by airway structural cells, recruitment/activation of inflammatory cells [5,7]
LRRC32 11q13 Regulatory T-cell function [9]
SMAD3 15q22 TGFE signalling intermediate, fibrosis [5]
ORMDL3/GSDMB 17q21 Sphingolipid synthesis (ORMDL3), cell apoptosis? (GSDMB) [4,5,8]
IL2RB 22q12 Binds IL-2/IL-15, lymphoid cell differentiation [5]
Genes focused on those meeting conventional genome-wide significance (p < 10 -8) and/or independent replication.
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suppression of inflammatory cell influx and function, inhibition 
of mucin production from airway epithelial cells and alterations in 
airway smooth muscle tone [79,80]. The two main PDE4 inhibitors 
that have reached Phase III development are roflumilast (Altana) 
and cilomilast (GlaxoSmithKline), and both compounds have 
shown some clinical efficacy in asthma, with primary end points 
being; baseline FEV
1
, early and late response to allegen (FEV
1
), 
morning peak expiratory flow and asthma symptom scores 
[81,82]. These compounds are second-generation PDE inhibitors, 
and have greater PDE4D selectivity and fewer side effects – for 
example, nausea.
The identification of PDE4D as an asthma susceptibility 
gene in 2009 further confirmed the importance of this enzyme 
in underlying mechanisms of relevance to asthma. The top 
SNPs identified involve predominantly intronic SNPs – that is, 
rs1588265 and rs1544791. However, these SNPs are in linkage 
disequilibrium with SNPs in the promoter region, therefore it is 
tempting to speculate that these SNPs may tag polymorphisms 
that influence mRNA expression and/or protein structure [6]. 
These findings are extremely pertinent to the recent report 
that suggested both PDE4D expression and PDE activity are 
increased (approximately twofold) in airway smooth muscle cells 
isolated from asthma patients compared with control subjects 
[83]. Importantly, this elevated PDE4D expression in the asthma 
airway smooth muscle was associated with approximately50% 
lower cAMP production in response to E
2
-adrenergic receptor 
agonists, including salbutamol and formoterol (in the presence 
of IBMX, a pan PDE inhibitor) [83]. Overall, these data suggest 
that SNPs within PDE4D are risk factors for the development 
of asthma and that alterations in PDE4D expression and 
activity are a feature of asthma patients airway smooth muscle 
influencing responses to E
2
-adrenergic receptor agonists. PDE4D 
SNPs may at least, in part, determine the clinical efficacy of 
PDE4D inhibitors, that is, these individuals have a subphenotype 
of asthma driven more by PDE4D dysregulation. Interestingly 
this class of drugs has several reported adverse effects including 
nausea, headache and diarrhea and thus, pharmacogenetics has 
the potential to avoid these effects in patients unlikely to respond 
to this specific therapy. We have identified SNPs spanning 
PDE4D as potential genetic determinants of FEV
1
 in a general 
population of 20,288 individuals, again suggesting a role for this 
enzyme beyond asthma [84].
To date, no Phase II or III trials of PDE inhibitors have been 
reported or retrospectively analyzed to include pharmacogenetics; 
however, based on the PDE4D GWA study data this would appear 
to be an opportunity. Similarly, an investigation of the role of 
PDE4D genotypes influencing E
2
-adrenergic receptor agonists 
is warranted.
Conclusion & expert commentary
A greater understanding of the pharmacogenetics of current 
asthma medications has the potential to maximize clinical 
outcomes and minimize adverse effects, leading to improvement 
in the management of asthma. There has been good progress in 
the last 5 years with larger prospective studies that importantly 
interrogate multiple SNPs in haplotypes instead of SNPs in 
isolation being completed. While predominantly candidate 
gene/pathway approaches have been used, genes that influence 
leukotriene modifier response, for example, ALOX5 and genes 
that influence glucocorticoid response, for example, FCER2 
have now been identified with confidence, showing independent 
replication for specific SNPs and direction of effect. Importantly, 
the magnitude of changes in clinical measures between 
genotypes including, for example, FEV
1
, can be considered 
clinically relevant. In addition, a large number of novel genes 
regulating responses to current asthma medications have 
been identified; however, these need further replication and 
validation. Interestingly, these pharmacogenetic effects account 
for a only a small proportion of the variability in response to 
these compounds and have been confounded by factors including 
SNP/haplotype analyses, gene–gene interactions and the relative 
contribution of SNPs in different ethnic backgrounds. While 
our knowledge has dramatically increased, there is a need for 
prospective trials of these current compounds involving large 
numbers of subjects and hypothesis-free approaches, including 
GWA studies.
To date, only one GWA study has been completed in asthma 
with respect to patient responses to current medication. This 
study identified a novel gene, GLCC1 as a determinant of 
corticosteroid responses using a hypothesis-free approach [63]. 
However, it is important to note that while the use of this 
hypothesis free approach is a strength of the study, the design of 
the study preselected the 100 most powered SNPs, meaning the 
vast majority of SNPs were not tested across the cohorts. Large, 
adequately powered GWA studies interrogating all available 
SNP data are required to truly identify novel markers of patient 
responses to existing asthma medications. Only then will the 
relative contribution of common genetic polymorphisms to drug 
responses to existing asthma medications be defined, leading to 
translation to clinical relevance. This is clearly a challenge for 
existing pharmacogenetic datasets as the majority of studies have 
been limited in sample size.
Many new compounds in development to treat asthma target 
specific mediators or pathways and it is unlikely these approaches 
will show utility in all asthma subjects. Preliminary data suggest 
careful patient selection for Phase II trials will be essential to 
adequately evaluate these new compounds for clinical efficacy, 
as exemplified by anti-IL-5 and anti-IL-13 trials in asthma. 
It is highly likely that these patient subphenotypes in asthma 
have a genetic basis. Supporting this, recent Phase II trials of 
IL-4/IL-13 dual antagonist (pitrakinra) suggest patient selection 
is critical to evaluating the clinical efficacy of this compound 
with specific IL4RD genotypes identifying responder groups. 
More pharmacogenetic integration is required for Phase II trials 
in asthma.
As the genetic basis of asthma is further defined by positional 
cloning, and more recently GWA studies new therapeutic 
opportunities are becoming apparent in specific pathways – for 
example, targeting the IL-33/ST2 interaction. In the evaluation 
of these new approaches, particularly Phase II clinical trials, it 
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will be essential that the most appropriate patients are targeted 
based on genotype within these studies.
The impact of our pharmacogenetic knowledge on asthma 
management and prescribing practice is limited at this time 
as there is a need to further define the complex genetic basis 
of responders/nonresponders or patients with/without adverse 
effects in large prospective studies for all drug classes. As 
technological developments move at a dramatic pace; for 
example, GWA study platforms comprising of a million common 
SNPs or several million rare SNPs, gene-expression studies and 
whole-exome or targeted resequencing, these approaches will 
allow unprecedented detailed analyses of the human genome in 
these patient subgroups. This drug-specific genetic profile likely 
involving many genes (e.g., receptors, signalling intermediates, 
transcription factors) may provide a step towards personalized 
medicine in asthma, with associated benefits including avoidance 
of adverse side effects and the adequate control of the patients’ 
asthma, avoiding exacerbation and hospitalization due to lack 
of control or potential fatal asthma. As the cost of these genetic 
platforms comes down, the potential of a relatively simple test 
reducing asthma treatment costs becomes a real possibility. 
However, the introduction of routine genetic testing into clinical 
practice will require a clear demonstration of health benefits 
and/or cost–effectiveness that outperforms the current stepwise 
approach to the management of asthma.
Five-year view
We anticipate that pharmacogenetic investigations will continue 
to focus on known targets for current asthma drugs and genes will 
be identified with confidence through replication. The greatest 
progress will be made when the full utility of GWA approaches 
is applied to large cohorts involving thousands of individuals. 
We anticipate many novel common variants/genes will be 
identified underlying responses to current asthma medication. 
This information will be critical for profiling responders/
nonresponders to existing asthma medications using multiple 
SNP markers across multiple genes, but importantly, may 
provide new insight into the mechanisms underlying the efficacy 
of existing drugs, leading to new therapeutic opportunities. If 
this information is going to impact clinical practice, there will 
be need for a simple, reproducible diagnostic test based on SNP 
combinations with adequately high specificity and sensitivity 
where responders and nonresponders are distinguished. This 
requirement is also a prerequisite for adequate evaluation of 
novel therapies in asthma – that is, conducting trials in the most 
appropriate populations likely to gain clinical benefit. Future 
challenges will be the handling of vast amounts of genomics 
information – GWA studies, whole-exomere-sequencing, 
expression profiling data and so on, and the standardization 
of clinical outcomes while accounting for nongenetic factors 
including the environment.
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Key issues
•฀ To date, the majority of pharmacogenetic studies have been limited in size and the number of polymorphic variants studied in one or 
multiple genes small, leading to inconclusive findings for current asthma medication.
•฀ In฀general,฀genotypes฀(single-nucleotide฀polymorphisms฀[SNPs])฀instead฀of฀haplotypes฀(combinations฀of฀SNPs฀spanning฀the฀gene฀of฀
interest) have been examined, potentially leading to conflicting data.
•฀ Larger prospective studies have now been completed and conclusions regarding specific variants are becoming clearer, although there 
has still been a lack of continuity of the clinical outcomes studied.
•฀ Where฀pharmacogenetic฀effects฀have฀been฀observed,฀these฀have฀been฀of฀a฀magnitude฀that฀can฀be฀considered฀clinically฀relevant;฀
however, larger prospective studies are required to accurately determine effect sizes.
•฀ To date, pharmacogenetic effects identified account for only a small proportion of the genetic variability in response to asthma 
medication (e.g., CRHR1 <3% of corticosteroid response), suggesting that asthma medications cannot be successfully personalized 
unless we resolve a larger degree of genetic variability and/or environmental influences.
•฀ Most pharmacogenetic studies in asthma have focused on pharmacodynamic aspects of drug responses; however, there is a need to 
carry out more pharmacokinetic investigations of current asthma medications, particularly for systemically administered drugs.
•฀ Technological฀advances฀allow฀the฀assessment฀of฀over฀1฀million฀SNPs฀in฀parallel฀(up฀to฀6฀million฀using฀imputation).฀These฀approaches฀are฀
needed to provide an unprecedented evaluation of the contribution of common genetic factors to drug responses in asthma. Additional 
approaches, including expression profiling analyses and resequencing to identify rare variants, are required to further define underlying 
genetic mechanisms. 
•฀ Asthma is a heterogeneous disease and newer therapies targeting specific mediators are unlikely to provide benefit in all subjects; 
therefore, there is an immediate need for the integration of pharmacogenetics (driving specific phenotypes) in Phase II trials of newer 
asthma drugs to adequately evaluate these drugs for clinical efficacy. 
Genetic basis for personalized medicine in asthma
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